- Home
- SPE vs MOLN Comparison
SPE vs MOLN Comparison
Compare SPE & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SPE | MOLN |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.8M | 170.5M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPE | MOLN |
|---|---|---|
| Price | $13.20 | $4.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 28.2K | 1.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.02 | $3.53 |
| 52 Week High | $15.85 | $5.36 |
Technical Indicators
Market Signals| Indicator | SPE | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 48.08 |
| Support Level | $13.02 | $4.13 |
| Resistance Level | $13.71 | $4.19 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 0.02 | 18.33 |
Price Performance
Historical ComparisonAbout SPE Special Opportunities Fund Inc
Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.